CompletedPhase 2

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

United States29 participantsStarted 2022-01-30

Plain-language summary

This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies * Have radiographically measurable disease by RECIST * Eligible for atezolizumab/bevacizumab front line therapy * Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent Exclusion Criteria: * Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan * Patients with higher than the weight/size limitations of PET/CT scanner

What they're measuring

Time to treatment response

Timeframe: Up to 12 cycles of treatment or 36 weeks

Progression free survival (PFS) at 6 months

Timeframe: At 6 months

Time to progression

Timeframe: Up to 3 years

Trial details

NCT IDNCT05176223

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Advanced Hepatocellular Carcinoma trials